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Examination Survey (NHANES). As a secondary goal, we contrasted prevalence estimates from the 2017 ACC/AHA guideline with those obtained using the 2014 Report From the Panel Members
Appointed to the Eighth Joint National Committee (JNC8 panel member report).(3).

Methods
NHANES is conducted by the National Center for Health Statistics of the Centers for Disease Control
and Prevention with the goal of monitoring the health status of the US general population.(4) Since 1999, NHANES has been conducted in two-year cycles. For each cycle, potential participants are identified through stratified, multistage probability sampling of the non-institutionalized US population. Using sampling weights, nationally representative estimates for the non-institutionalized US population can be generated and NHANES cycles can be combined to provide more stable prevalence estimates when needed. For the current analysis, we pooled data from the 2011-2012 and 2013-2014 NHANES cycles. The current analysis was restricted to adult participants, 20 years of age and older (n=10,907). Participants who did not have three SBP and DBP measurements obtained during their study visit (n=704) or were missing data on self-reported antihypertensive medication (n=13) were excluded. Also, participants missing data on variables (age, gender, race, smoking, total and HDL-cholesterol, and diabetes) used to calculate 10-year predicted CVD risk according to the Pooled Cohort risk equations (n=567) were excluded. After these exclusions were applied, data from population. Using sampling weights, nationally representative estimates for the no on n n-in in inst st stit it itut ut utio io ion na n li US population can be generated and NHANES cycles can be combined to provide more stable prevalence estimates when needed. 
Data collection
NHANES data were collected through the administration of standardized questionnaires and a medical evaluation at a mobile examination clinic. Covariates included in this analysis and their method of ascertainment are described in Online Table 1 .
Blood pressure measurement and antihypertensive medication use
BP was measured by a trained physician using a mercury sphygmomanometer and an appropriately sized cuff. Cuff sizes were selected after measurement of each participant's mid-right arm circumference. Readings were obtained after 5 minutes of seated rest. Three blood pressure measurements were obtained at 30 second intervals. The mean of the three measurements was used to define SBP and DBP. Quality control included quarterly re-certification with retraining as needed, and annual retraining of all physicians. Certification required video test recognition of Korotkoff sounds and performing measurements on volunteers. Participants who responded affirmatively to both of the questions "Have you ever been told by a doctor or other healthcare professional that you had hypertension, also called high blood pressure?" and "Are you now taking prescribed medication for high blood pressure?" were considered to be taking antihypertensive medication.
Cardiovascular disease (CVD) risk
History of CVD was defined by self-report of a prior diagnosis of myocardial infarction, coronary heart disease, stroke or heart failure. Among those without a history of CVD, 10-year predicted CVD risk was calculated using the Pooled Cohort risk equations. The 2017 ACC/AHA and JNC7 guideline and JNC8 panel member report definitions of hypertension, criteria for recommending antihypertensive medication, and recommended BP goals for adults taking antihypertensive medication are provided in Table 1 .
Statistical Analysis
We calculated the distribution of the population across five groups including those not taking antihypertensive medication with SBP/DBP < 120/<80, 120-129/<80, 130-139/80-89, 140/90 mm Hg and those taking antihypertensive medication. These levels represent the BP stages in the 2017 ACC/AHA guideline (Online Table 2 ). Participants with SBP and DBP in two categories (e.g., SBP< 120 mm Hg and DBP between 80 and 89 mm Hg) were designated into the higher category.
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NHANES sampling weights were used in all calculations to obtain US nationally representative prevalence estimates. These weights were recalibrated based on the proportion of participants missing data by age, gender, and race-ethnicity within each NHANES cycle.
Recalibration of the sampling weights corrects for differences in missing data across age, gender and race-ethnicity strata and assumes that data within strata are missing at random.(6) Data management was conducted in SAS version 9.4 (SAS Institute, Cary, NC) and data analysis was conducted in Stata V14 (Stata Corporation, College Station, TX).
Results
In 2011-2014, 42.3%, 12.1%, 13.7% and 7.7% of US adults not taking antihypertensive medication had SBP/DBP levels of <120/80, 120-129/<80, 130-139/80-89, and , respectively (Table 2) . Additionally, 24.1% of US adults were taking antihypertensive medication. US adults with higher BP were older, more likely to be non-Hispanic black, taking a statin, and have diabetes, reduced eGFR, albuminuria and a history of CVD. Total cholesterol levels and mean 10-year predicted CVD risk were higher at higher BP levels.
The prevalence of hypertension was 45.6% and 31.9% according to the 2017 ACC/AHA and JNC7 guideline definitions, respectively ( Table 2 ). ) Additionally, 24.1% of US adults were taking antihypertensive medication. US adults high h he e er BP were re e old ld lder, , mo mo more re r lik ik ikel el e y y y to to to be e non-Hi Hi H span anic b b bla la lack ck ck, ta t t ki king ng ng a a s sta tatin, n, n, a a and nd nd ha ha h ve d dia ia iabe be bete te tes, s s edu du uc ce c d eGFR R R, al a a bu bum min nuria a a a an a d a histor ory of C C CVD VD. To o ota ta tal l l ch h chol o e este ero ol le ev vels and mea ea e n n 10 0-r year r predicted CV VD risk k were higher at higher BP P levels. Compared with US adults defined as having hypertension according to the JNC7 guideline, those with hypertension defined by the 2017 ACC/AHA guideline but not the JNC7 guideline were younger, had lower total cholesterol, SBP, DBP and 10-year predicted CVD risk levels, and were less likely to have diabetes, reduced eGFR, albuminuria and a history of CVD (Online Table 3 ). Those recommended antihypertensive medication by the 2017 ACC/AHA guideline but not the JNC7 guideline had lower mean SBP and DBP levels but a higher mean 10-year CVD risk than their counterparts recommended antihypertensive medication by the JNC7 guideline. Also, US adults in this group were older, more likely to be male, non-Hispanic white, cigarette smokers, and have a history of CVD.
Among US adults taking antihypertensive medication, 53.4% had above goal BP according to the 2017 ACC/AHA guideline compared to 39.0% with above goal BP according to the JNC7 guideline ( Table 5) . BP above goal, defined using thresholds from the 2017 ACC/AHA guideline instead of the JNC7 guideline, was more than 10 percentage points higher in each sub-group investigated except for , ACC/AHA guideline compared with the JNC7 guideline.
Compared with US adults defined as having hypertension according to the JNC7 guidelin Table 6 ). Table 7 ).
Discussion
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